Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

Autor: Laurence Clement, Yves Beguin, Alain Duhamel, Pierre Fenaux, Eric Deconinck, Marie-Thérèse Rubio, Ibrahim Yakoub-Agha, Aline Schmidt-Tanguy, Claude-Eric Bulabois, Pierre Bories, Jean-Pierre Marolleau, Gandhi Damaj, Jean El Cheikh, Mohamad Mohty, Lionel Ades, Stephane Vigouroux, Zora Marjanovic, Faeyzeh Legrand, Natacha Maillard, Charles Dauriac, Anne Huynh, Jérôme Cornillon, Jacques-Olivier Bay, Gaelle Guillerm, Sophie Park, Nathalie Fegueux, Mauricette Michallet, Marie Robin, Alice Garnier, Federico Garnier

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, 2012, 30 (36), pp.4533-40. ⟨10.1200/JCO.2012.44.3499⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2012, 30 (36), pp.4533-40. 〈10.1200/JCO.2012.44.3499〉
Journal of Clinical Oncology, American Society of Clinical Oncology, 2012, 30 (36), pp.4533-40. ⟨10.1200/JCO.2012.44.3499⟩

Purpose To investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell transplantation (alloSCT) for myelodysplastic syndrome (MDS). Patients and Methods Of the 265 consecutive patients who under

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be694ab560db08eec073e5172cb47ac7
https://www.hal.inserm.fr/inserm-00821506/document